Pleuropulmonary blastoma treatment market is expected to reach US$ 995.33 Million by 2033 | Merck & Co., Inc., Pfizer Inc., Baxter, and Eli Lilly and Company

Global pleuropulmonary blastoma treatment market size reached US$ 649.44 Million in 2024 from US$ 621.08 Million in 2023 and is expected to reach US$ 995.33 Million by 2033, growing at a CAGR of 4.9% during the forecast period 2025-2033.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/pleuropulmonary-blastoma-treatment-market?sg

Market growth drivers:

✅ Rising genetic diagnostics & registries - wider adoption of DICER1 genetic testing and rare-tumour registries improves early detection (Type I cases), increasing treated patient counts and demand for follow-up care.

✅ Orphan-drug & R&D focus - stronger pharma investment into rare-disease oncology, incentives for orphan approvals and precision therapies (case reports of targeted responses) are attracting drug development to PPB.

✅ Multidisciplinary care and pediatric oncology hubs - advanced paediatric cancer centers (surgery + chemo + radiation + clinical trials) concentrate capability, raising treatment rates and supporting higher per-patient revenues.

✅ Clinical trials & precision cases - increasing registry-backed trials and case reports (e.g., gene-mutation responsive targeted agents) boost pipeline activity and future addressable therapies.

Clinical & Research / Treatment Developments (2025):

➠ 2025 (Feb) - A review article from International PPB/DICER1 Registry reported that the Registry has assembled its largest‐ever cohorts of type I/Ir and type II/III PPB. This expanded dataset provides the foundation for a planned prospective consortium-based clinical trial evaluating camptothecins in type II/III PPB; and for efforts to standardize chemotherapy use in type I PPB.

➠ 2025 (March 21) - A new clinical trial for PPB, identified as protocol ARAR2331, was initiated by Children's Oncology Group. The trial will test effectiveness of surgery + chemotherapy (and in some arms, adding topotecan) for types I, II and III PPB.

➠ 2025 (2025 cohort study) - A nationwide multicenter study published in October 2025 reviewed 15 children treated for PPB (diagnosed between 2011-2024), with a median age ~39 months. All had surgery plus postoperative chemotherapy; no patients received radiotherapy as first-line treatment. Despite multimodal therapy, progressive or relapsed disease - especially with CNS involvement occurred in some, underlining persistent risk and need for improved therapy.

➠ 2025 (Jan) - A case report published described a child with type III PPB (3‐year-old female) treated with surgery + standard chemotherapy; at follow-up she was doing well without recurrence. The report emphasized the importance of early imaging, prompt histopathology + molecular testing (e.g. for DICER1), and long‐term surveillance of families.

➠ 2025 (2025 pathological‐molecular findings) - A prognostic study from the Registry found that high expression of TP53 (p53) on immunohistochemistry (IHC) is significantly associated with worse recurrence-free survival and overall survival among PPB patients (types II/III). This suggests p53 IHC may serve as a risk‐stratification tool at diagnosis helping guide aggressiveness of therapy.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/pleuropulmonary-blastoma-treatment-market?sg

Regional share:

➠ North America - largest market due to premier pediatric oncology centers, routine DICER1 testing, high orphan-drug uptake and favourable reimbursement, driving majority revenue share. US dominance is repeatedly cited by market reports and treatment-center data.

➠ Europe - growing share from coordinated paediatric oncology networks, increasing genetic screening and EU research collaborations; uptake trails North America but is steadily rising.

➠ Asia-Pacific & Rest of World - smaller current shares due to limited rare-disease infrastructure and diagnostics, but expanding investment, awareness and clinical programs signal faster relative growth rates.

Segments Covered in the pleuropulmonary blastoma treatment Market:

By Disease Type (Type I Pleuropulmonary Tumors, Type II Pleuropulmonary Tumors, and Type III Pleuropulmonary Tumors)

By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, and Others)

By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others)

Regional Analysis for pleuropulmonary blastoma treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=pleuropulmonary-blastoma-treatment-market?sg

Major Key Players: Merck & Co., Inc., Pfizer Inc., Baxter, and Eli Lilly and Company.

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, pleuropulmonary blastoma treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global pleuropulmonary blastoma treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global pleuropulmonary blastoma treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the pleuropulmonary blastoma treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.